account adjust acquisition-rel cost certain
signific item
revis model post result io model updat verubecestat piii failur
execut well io result keytruda close lead
posit weaker trend hand key product temper outlook view
share fairli valu current level new pt
updat model reflect coupl factor affect io
compani keytruda sale estim increas modestli
thereaft forecast trim
new assumpt detail
affect number assum rhhbi garner equal share
nsclc pend clariti combo studi slower previous
forecast sale evolut ou market io overal ou sale forecast fell
ep estim increas vs guidanc
consensu vs consensu
thereaft forecast reduc
ep peg reduct ep forecast
vs prior estim impli ep compound-annual-growth-rate vs previous
lower price target base reduc target multipl
ep estim given less posit long-term outlook
sale estim increas vs guidanc
howev
sale forecast cut result three factor
reduct keytruda mention elimin verubecestat model
post second fail phase alzheim trial cut januvia contempl
 eu patent expir forecast peg impli
sale compound-annual-growth-rate vs previous
oper margin forecast intact flat y/i thereaft
lower forecast
despit cut still look margin
improv also forecast tax rate although
suggest might room improv
pleas see page report import disclosur
merck competit posit line lung cancer clear posit advantag may
finit bring data io/io combin merck posit io/
io combin less clear merck face uncertainti well includ januvia
outlook competit market remicad zetia vytorin cubicin nasonex
biosimilars/gener competit pressur isentress zostavax believ risk
balanc opportun therefor remain market perform stock
uptak keytruda nsclc
keytruda chemo combo nsclc
keytruda data readout variou tumor
lynparza data/fil ovarian
oper margin improv
keytruda data and/or uptak lung
posit expect
new product unabl off-set nasonex
vytorin/zetia cubicin patent
expir competit pressur
zostavax isentress
merck global health care compani includ prescript medicin vaccin
biolog therapi anim health strong product presenc oncolog
cardiovascular anti-infect anti-inflammatori diabet area among other
anim health divis focus mainli feed anim
cowen compani
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
cowen compani
 patent expir glenmark enter month exclusivityzetia patent expir ezetimibecozaar/hyzaar arb hypertens gener competitionvytorin exclus laps patent expir ezetimibe/simvastatin improve-it achiev endpoint garner fda labelintegrilin revenu repurchas milleniumzocor cholesterol reduct patent expir develop riociguat solubl guanyl cyclas sgc modul approv eu pah cteph japan phase heart failur victoria ref-hf studi underway part bayer zetia lipitor market eu market patent expir littl eros japan despit patent market bridion market eu japanbridion sugammadex anesthesia revers suvorex insomnia orexin neuropeptid approv us japan like tier coverag yet file eu schizophrenia phase iiremeron antidepress patent expir januari major sale ex-u maxalt/maxalt mlt patent expir maxalt/maxalt mlt patent expir eumaxalt/maxalt mlt agonist anesthesia patent expir cowen
cowen compani
 share qd market unlik blunt erosionisentress qd approv eu hiv integras inhibitor treatment resist nave approv gilead gsk tivicay pose competitionnoxafil patent expir eu patent expir posaconazol oral antifung approv prophylaxi oral candidiasi cubicin advers court decis allow gener first gener teva launch sale nv modest royaltiescubicin cubist acquir launch competit landscap pressureszepati launch eu japan competit landscap pressureszepati hepat grazoprevir proteas inhibitor elbasvir competit landscap ceftolozane/tazobactam ww right ex asia-pacif gram neg infect approv phase habp/vabp bezlotoxumab tx difficil associ diarrhea cdad approv medarex/ma biolog difficil tedizolid gram posit infect launch phase habp/vabp bacteri pneumonia relebactam imipenem/cilastatin bacteri infect phase cmv prophylaxi transplant patient nnrti hiv posit phase data croi dose qd good safeti file roch pegasys/copegu pressur new drug clip durat therapyintron support use oncolog applicationsribavirin/rebetol older modalityintron substanc patent expir formul patent expir settlement allow gener launch aug ou patent expiredcancida antifung qd iv new indic price share eros due competitioninvanz patent expir compound composit invanz broad spectrum carbapenem oral im iv qdprimaxin emerg market-drivenprimaxin bolster sale effort blunt eros patent expir proteas inhibitor aid stocrin certain fgn mkt patent exp older antibioticstot cowen
cowen compani
 golimumab ra pa uc approv eu canadaremicad crohn uc ra pa earli ra psoriasi patent expir biosimilar exposur marketsarcoxia approv market countriestot approv tumor type includ melanoma lung chl bladder msi-hkeytruda eu approv melanoma lung chl bladderkeytruda antibodi mani tumor type saha cutan t-cell lymphoma roll-out underway clinic trial underwayemend aprepit substanc antagonist emesi patent exp oral iv franchis oral/ivtemodar teva launch gener gener japan pat exp eu temodar chemotherapeut aa gbmazn lynparza/selumetinib record sale net cog sg record linetot gener launch over-the-counter product also pressurenasonex gener eu allerg rhinitisdulera asthma market copd longer pursu dulera launch copd four market asthma market dulera mometasone/formoterol competit dynam pressuresingulair patent expir patent expir eu includ month pedi exclus japansingulair asthma phase cough includ cough idiopath pulmonari fibrosi phase iiasmanex market asmanex market countriesasmanex asthma dri powder qd inhal corticosteroid patent devic formul expir beta agonist asthma cfc hfa complet cowen
cowen compani
 continuedclarinex small market retainedclarinex claritin rx/otc sold bayer ag tax part consum transact close asthma older product europetot nrx share patent expir pedi exclus could add monthsjanuvia/steglatro/combo patient expir qd antidiabet competit threat given proven cv ertugliflozin diabet inhibitor w/ approv mono ertugliflozin/sitagliptin ertugliflozin/metformin omarigliptin diabet qweek inhibitor market japan file plan diabet mellitu insulin glargin biosimilar file approv eu diabet mellitu dual agonist antibodi phase iitot competit gsk shingrix prompt zostavax declin sale reflect dissolut spmsd jv ad herp zoster vaccin adult year singl sq dose plu booster investigatedproquad mmr ii varivax mmr ii varivax sale reflect dissolut spmsd jv ad mmr ii varivax could support health initiativesrotateq sale reflect dissolut spmsd jv ad rotaviru vaccin oral liquid good safeti profil market ww competit gskgardasil/gardasil approv year old femal male sale gardasil two dose approv fda/cdcgardasil/gardasil sale reflect dissolut spmsd jv ad approv two dose regimen china launch boostsgardasil/gardasil hpv vaccin borrow cdc stockpil refil hexaval combin pediatr vaccin approv eu nda issu inactiv herp zoster vaccin phase pneumoconjug vaccin phase iipneumovax prevnar pressuringpneumovax pneumococc vaccin adultstot cowen
cowen compani
 psoriasi moder potenc steroid patent exp compound cream lotion implanon/nexplanon implant contracept patent expir juli progesteron/estrogen market eu exclus pursu corifollitropin alpha infertil market eu exclus pursu nuvar patent expir april contracept vagin contracept patent expir septemb aq aq aq follitropin beta inject patent expir june oral contracept patent expir decemb contracept patent expir septemb oral contracept patent expir march contraception/women cowen
cowen compani
 bph gener competit fosamax osteoporosi gener launch patent expir bald domin small acceler time upper lower gi recoveri post surgeri cubistoth ivomec merial othertot healthanim bravecto oral approv may key driveranim mainli feed animalsanim busi spin/split/sal possibl guidanc cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl januvia vytorin
zetia isentress success pipelin product especi suvorex odanacatib
anacetrapib lambrolizumab success deal patent litig patent
expir pressur binari risk includ safeti issu involv odanacatib
improve-it studi vytorin
